10-Q: Strata Critical Medical: Q3 Net Income Soars, Medical Segment Grows

Strata Critical Medical reported a significant net income increase in Q3 2025, driven by the divestiture of its Passenger business and strong growth in its core Medical segment, bolstered by the Keystone acquisition.

Summary

• Strata Critical Medical, Inc. reported a net income of $57,416,000 for the three months ended September 30, 2025, a substantial improvement from a net loss of $1,954,000 in the prior year period.
• This improvement was primarily driven by a $60,435,000 gain on the sale of its Passenger business to Joby Aero, Inc. on August 29, 2025.
• The company's continuing operations (Medical segment) saw revenue increase by 36.7% to $49,298,000 for the three months ended September 30, 2025, and by 18.0% to $130,354,000 for the nine months ended September 30, 2025.
• Adjusted EBITDA from continuing operations significantly improved to $4,214,000 for the three months ended September 30, 2025, up from $67,000 in the prior year, and to $7,096,000 for the nine months, up from $2,677,000.
• The acquisition of Keystone Perfusion Services, LLC on September 16, 2025, for $109,963,000 cash and 3,434,609 shares (valued at $16,828,000), contributed approximately $2,800,000 to revenue in the quarter.
• Net loss from continuing operations worsened to $9,657,000 for the three months and $14,678,000 for the nine months ended September 30, 2025, compared to $5,627,000 and $8,731,000 respectively in the prior year periods.
• Cash used in operating activities significantly increased to $40,607,000 for the nine months ended September 30, 2025, from $767,000 in the prior year.
• Total liquidity (cash and short-term investments) decreased from $124,800,000 at December 31, 2024, to $75,900,000 at September 30, 2025.

Sentiment

Score: 6

Explanation: The company achieved a significant net income due to the divestiture of its Passenger business, which is a positive strategic move to focus on its core medical segment. The Medical segment itself shows strong revenue growth and improved Adjusted EBITDA and margins. However, the net loss from continuing operations has worsened, and cash used in operating activities has increased substantially, leading to a decrease in overall liquidity. The Keystone acquisition adds growth potential but also integration risks and contingent liabilities. The ongoing legal proceedings also present a concern.

Positives

• Net income for the three months ended September 30, 2025, was $57,416,000, a significant turnaround from a $1,954,000 net loss in the prior year.
• Net income for the nine months ended September 30, 2025, was $50,180,000, a substantial improvement from a $17,514,000 net loss in the prior year.
• Revenue from continuing operations increased by 36.7% to $49,298,000 for the three months and 18.0% to $130,354,000 for the nine months ended September 30, 2025.
• Adjusted EBITDA from continuing operations saw a dramatic increase to $4,214,000 (Q3 2025) from $67,000 (Q3 2024), and to $7,096,000 (9M 2025) from $2,677,000 (9M 2024).
• Gross Margin for continuing operations improved to 19.4% in Q3 2025 from 15.0% in Q3 2024, and Flight Margin improved to 23.6% from 20.8%.
• The acquisition of Keystone Perfusion Services, LLC expands the company's offerings in surgical organ recovery and normothermic regional perfusion, contributing approximately $2,800,000 to revenue in the quarter.
• The company anticipates sufficient funds to meet operational needs for at least the next 12 months.
• Operating loss from continuing operations improved to $(5,622,000) (Q3 2025) from $(7,092,000) (Q3 2024) and to $(15,948,000) (9M 2025) from $(16,621,000) (9M 2024).

Negatives

• Net loss from continuing operations worsened to $9,657,000 for the three months and $14,678,000 for the nine months ended September 30, 2025, compared to $5,627,000 and $8,731,000 respectively in the prior year periods.
• Cash used in operating activities significantly increased to $40,607,000 for the nine months ended September 30, 2025, from $767,000 in the prior year.
• Total liquidity (cash and short-term investments) decreased from $124,800,000 at December 31, 2024, to $75,900,000 at September 30, 2025.
• A realized loss of $5,195,000 from the sale of short-term investments was recorded for both the three and nine months ended September 30, 2025.
• Interest income decreased to $1,127,000 (Q3 2025) from $1,764,000 (Q3 2024) and to $3,603,000 (9M 2025) from $5,624,000 (9M 2024) due to lower invested balances.
• General and administrative expenses increased due to legal expenses related to the Drulias lawsuit and M&A transaction costs for the Keystone acquisition.
• The evaluation of internal controls over financial reporting did not include Keystone, which represented a significant portion of total assets (39.9%) and sales (2.1%) from continuing operations.

Risks

• Continued occurrence of net losses from continuing operations.
• Inability to realize anticipated benefits from the Passenger business divestment and Keystone acquisition, including the receipt of contingent consideration.
• Potential changes to aircraft ownership and related operational and business challenges.
• Intense competition in the organ logistics marketplace and clinical service offerings.
• Reliance on contractual relationships with transplant centers, hospitals, and Organ Procurement Organizations.
• Reliance on certain major customers (one customer accounted for 13% of revenue for the three and nine months ended September 30, 2025).
• Uncertainty regarding the continuing availability of organ donors and viable donor organs, with recent months showing decreased availability.
• Insufficient reimbursement and funding for organ transport costs.
• Risks related to organ transport operations, including new technology that could make ground or commercial air transport more viable.
• Negative publicity, reputational damage, litigation, claims, or investigations related to the provision of clinical services and perfusion staffing services.
• Regulatory changes, legislative reforms, and civil or criminal enforcement actions.
• Challenges in successfully integrating Keystone and future acquisitions.
• Impact of natural disasters, outbreaks, pandemics, economic, social, weather, growth constraints, geopolitical, and regulatory conditions.
• Adverse publicity stemming from accidents involving small aircraft, helicopters, or charter flights, particularly those involving third-party operators.
• Effects of climate change, terrorist attacks, geopolitical conflict, or security events.
• Availability of aircraft fuel and potential increases in costs.
• Ability to access additional funding to finance operations.
• Ability to manage growth effectively.
• Increases in insurance costs or reductions in insurance coverage.
• Loss of key members of the management team.
• Disruptions to third-party operators and providers workforce.
• System failures, defects, errors, or vulnerabilities in technology systems, especially with increased usage of artificial intelligence (AI).
• Inability to remediate any material weaknesses or maintain effective internal controls over financial reporting.
• Historical financial statements may not be comparable due to the impact of discontinued operations.

Future Outlook

The company anticipates sufficient funds to meet its current operational needs for at least the next 12 months. Longer-term liquidity requirements will depend on factors such as market expansion, customer retention, capital expenditures, and future acquisitions. The company may seek external financing in the future to capitalize on market opportunities.

Management Comments

• Our mission is to increase the number of organs that are successfully transplanted while leveraging the Company's expertise and resources to provide other medical and logistics services to a broader customer base.
• We believe that, by working with Strata, industry participants can save money, save more lives and operate more efficiently.
• We made the decision to invest in a limited number of owned aircraft based in high-volume geographies as we believe direct asset ownership will enable (i) improved economies of scale; (ii) increased uptime, enabling more reliable service and higher asset utilization; and (iii) the ability to compete for certain contracts where asset ownership is preferred or required.
• We prioritize the use of owned aircraft and dedicated aircraft under CPAs, which provide better economies of scale. We size our owned fleet and our commitments under CPAs significantly below our expected demand, enabling us to maximize utilization on those aircraft while fulfilling incremental demand through our network of non-dedicated operators.
• We have responded to customer demand by introducing new services through our acquisition of Keystone, which enabled us to provide surgical recovery, NRP and other related clinical services as part of an end-to-end offering.
• We have also added new offerings organically, such as our TOPS organ placement offering, whereby we assist customers in evaluating the suitability of potential donor organs for transplant.
• We have historically passed through cost inflation to customers and most logistics contracts with customers automatically pass through any fuel surcharges, but there is no guarantee this will continue in the future.

Industry Context

The company operates in the time-critical medical logistics and services sector, specifically organ transplant. This industry is experiencing growth driven by increased utilization of Donation after Circulatory Death (DCD), advancements in technology like machine and regional perfusion, and regulatory changes for organ allocation. However, recent months have shown decreased availability of donor organs, posing a challenge. The market is competitive, with players competing on reliability, end-to-end service, and increasingly, integrated logistics and clinical offerings. The acquisition of Keystone aligns with the trend of offering comprehensive solutions to meet customer demand for integrated services.

Management Changes

Corporate Governance

Legal Proceedings

• Two putative class action lawsuits, Drulias et al. v. Affeldt, et al., C.A. No. 2024-0161-SG (Del. Ch.), were filed in February 2024 and consolidated on April 16, 2024.
• Plaintiffs assert claims for breach of fiduciary duty and unjust enrichment against former directors and officers of Experience Investment Corp. and Experience Sponsor LLC, and aiding and abetting breach of fiduciary duty against Sponsor.
• The complaint alleges insufficient disclosure in the proxy statement related to the acquisition of Old Blade regarding EIC's cash position, Old Blade's value prospects and risks, and information related to Old Blade's former CEO.
• The consolidated complaint seeks damages and attorneys' fees and costs. Litigation is ongoing, and the company has included a provision for the expected resolution in its financial statements.

Related Party Transactions

• The sale of the Passenger business to Joby Aero, Inc., a wholly-owned subsidiary of Joby Aviation, Inc., involved the transfer of the former CEO, Robert Wiesenthal, to Joby Buyer, and the modification of his equity awards. This transaction includes ongoing contingent consideration.
• The "Transition and Transaction Bonus Agreement" with former CEO Robert Wiesenthal, modifying his outstanding equity awards, is a related party transaction.

Stakeholder Impact

• Shareholders: Potential for increased value from strategic focus on the Medical segment and successful integration of Keystone. However, dilution risk from equity consideration in acquisitions and potential future capital raises. Ongoing litigation (Drulias) poses a financial and reputational risk.
• Employees: Former CEO transferred to Joby Buyer, with modified equity awards. New Co-CEOs appointed. The acquisition of Keystone brings new employees into the company.
• Customers: Expanded service offerings (surgical recovery, NRP, organ placement) through Keystone acquisition and organic growth (TOPS) aim to provide more comprehensive solutions and efficiency.
• Suppliers/Operators: Continued reliance on third-party aircraft operators and vendors, with capacity purchase agreements in place.
• Creditors: Liquidity decreased, but management believes funds are sufficient for the next 12 months. Contingent consideration liabilities exist.

Next Steps

• Determine final adjustment for Keystone's 2025 adjusted EBITDA performance by March 2026.
• Settle contingent equity consideration for Keystone acquisition in the second quarter of 2026.
• Potentially receive up to an additional $35,000,000 in contingent consideration from Joby Buyer based on financial performance and employee retention targets within 12 and 18 months following the Passenger business sale.
• Potentially receive release of up to $10,000,000 in indemnity holdbacks from the Passenger business sale.
• Continue to integrate Keystone Perfusion Services, LLC into operations.
• Address ongoing litigation related to the Drulias lawsuit.
• Evaluate the impact of recently issued accounting pronouncements (ASU 2023-06, 2023-09, 2024-03, 2025-05, 2025-06).

Key Dates

Recommendation

Strata Critical Medical is undergoing a significant strategic transformation, divesting its non-core Passenger business and acquiring Keystone to strengthen its Medical segment. While the divestiture generated substantial net income and the Medical segment shows strong revenue growth and improved Adjusted EBITDA, the core continuing operations still report net losses and increased cash burn from operations. The long-term success hinges on the effective integration of Keystone, realization of anticipated synergies, and successful navigation of contingent consideration and ongoing legal challenges. The decrease in overall liquidity and the worsening net loss from continuing operations warrant a cautious approach. A "hold" recommendation allows investors to observe the execution of the new strategy and the company's ability to achieve profitability in its focused medical operations before making a more definitive investment decision.

Keywords

Medical logistics, Organ transplant, Healthcare services, Perfusion services, Organ recovery, Air transport, Ground transport, SEC filing, 10-Q, Quarterly report, Acquisition, Divestiture, Financial results, Adjusted EBITDA, Keystone Perfusion, Joby Aviation, SRTA